A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes

Inclusion Criteria: For Part A and B * Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form * Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator. * Have a stable body weight (\< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening * Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses fo…